retatrutide nejm 2023 obesity trial ly3437943 Incretin triple agonist (LY3437943) alleviates obesity-associated cancer progression First Retatrutide phase 3 data,

Our approach which is built on a decade of experience working with and without GLP-1s to reverse type 2 diabetes enables members to lose weight sustainably and maintain their results." In line with these new findings, Virta announced the expansion of its Sustainable Weight Loss solution, a comprehensive approach to weight loss that enables employers and payers to offer responsible and individualized use of GLP-1s

The compounded tier requires specific diligence, and the reasons should be stated plainly

However, a small study that gave a group of alcoholics a low dose of semaglutide (Wegovy) over nine weeks showed an improvement in their drinking habits, including a reduction in cravings and heavy drinking days

I must say

Some practitioners recommend delaying food intake for 30-60 minutes post-injection to allow the peptides peak effects to occur in the continued fasted state

If injecting yourself weekly is the dealbreaker, thats the path